The Future of IBD Care: Pfizer Leads a New Era of Noninvasive Monitoring (Pfizer)

For patients with IBD, monitoring the disease often means enduring repeat colonoscopies—uncomfortable, invasive, and time-consuming. But Pfizer is helping change that.Their new push centers on intestinal ultrasound (IUS)—a noninvasive, real-time alternative that requires no sedation, no prep, and no recovery time. Endorsed by ECCO and now supported by the global PRISM consortium (launched by Pfizer and partners), IUS could dramatically improve patient comfort and access, while catching flare-ups earlier.